In 2025, we partnered with many patients, families, and foundations through rareSHIFT™. This year, we partnered with 18 new foundations.  

rareSHIFT™ studies entail making Living Molecular Twins of patient populations based on real patient data. We help families and foundations accelerate their therapeutic odysseys, predicting which existing therapeutics will be the most efficacious, while also indicating which mechanisms should be targeted. Starting in patients enables understanding of how a patient population will respond prior to extensive research into a single drug target that does not have guaranteed success.

Our work with patient populations identifies deep insights about patient populations, often identifying multiple subgroups within a population that respond to therapeutics similarly. Not only do these studies identify the minimum number of molecules needed to treat the maximum number of patients, but they also pave the way for us to defragment rare disease, looking for similar drug responders not just within a disorder but across various disorders, creating larger groups of therapeutic responders to create commercially viable markets for molecules.  

In addition, we began a collaboration with COMBINEDBrain to enable large-scale drug discovery for rare neurological disorders. This collaboration will catalyze our goal of defragmenting rare disease. As a consortium for rare neurological disorder advocacy groups, COMBINEDBrain will accelerate its members’ efforts to identify drug candidates and therapeutic mechanisms through the rareSHIFT™ program. Thus, Unravel can identify shared mechanisms to further syndicate our drug development approach and defragment rare disease.